[Skip to Navigation]
Health Care Policy and Law
June 1, 2020

Expensive Insulin—The Epicenter of a Large, Life-Threatening Problem

Author Affiliations
  • 1Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut
  • 2Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
JAMA Intern Med. 2020;180(7):931-933. doi:10.1001/jamainternmed.2020.1299

For millions of people with diabetes, including those with type 1 diabetes, access to insulin can be a matter of life and death. Shortly after discovering insulin in 1921, Banting, Best, and Collip sold the original patent to the University of Toronto (in Canada) for just $1, with the intention of giving affordable access to this life-saving drug to all individuals who needed it.1 In the 1980s, the development of recombinant DNA technology allowed drug manufacturers to inexpensively produce a seemingly unlimited supply of biosynthetic insulin using the cellular machinery of bacteria and yeast.2 Today, although a vial of insulin is estimated to cost no more than US $3 to $6 to produce,3 its skyrocketing price has threatened access to the drug. A vial of Humalog (insulin lispro), which cost $21 in 1996, now costs $250 to $400.4 Insulin pricing exemplifies the problem with a health care system that allows charging an exorbitant amount of money for life-saving medications.

Add or change institution
1 Comment for this article
Traditional Insulin
Jay Caplan, B.S. | commercial - manufacture
Not familiar with diabetes, but I note that traditional insulin - short and intermediate acting Novolin - is $25/vial of 1000 units with GoodRx at Walmart, $14 with cheapest Part D Medicare plan.

Isn't this a case of saying everyone should have the newest and best branded drug, without paying its full price ? If not affordable, could most most patients do well on traditional insulin ?